Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: Alkem Laboratories Ltd., INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC#: 67877-434-05

Out of specification (OOS) for Spectroscopic Identification test by IR.

Recall #: D-0539-2023
Affected scope: 135 bottles
Initiated: March 17, 2023

Compiled from official public sources by the publisher. · Updated September 2026

Ascend Laboratories, LLC recalled Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: … - a moderate-severity action.

Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: … was recalled by Ascend Laboratories, LLC in April 26, 2023. Reason: Out of specification (OOS) for Spectroscopic Identification test by IR.. Check the official notice for the remedy. Verify recall #D-0539-2023 with the FDA Drug before acting.

The recall

Ascend Laboratories, LLC issued this moderate-severity FDA Drug recall-Out of specification (OOS) for Spectroscopic Identification test by IR..

Moderate
severity level: Class II
classification: April 26, 2023
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0539-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: Alkem Laboratories Ltd., INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC#: 67877-434-05

Reason for recall

Out of specification (OOS) for Spectroscopic Identification test by IR.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Ongoing
Recall number	D-0539-2023
Date reported	April 26, 2023
Date initiated	March 17, 2023
Recalling firm	Ascend Laboratories, LLC
Firm location	Parsippany, NJ
Affected scope	135 bottles
Distribution	Nationwide in the USA

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0539-2023) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Out of specification (OOS) for Spectroscopic Identification test by IR.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on April 26, 2023. Severity: Moderate. Recall number: D-0539-2023.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the USA.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Verapamil Hydrochloride Extended-Release … 2023-04-26 Fast Acting Earwax Removal System (carbam… 2023-04-26 C-Semaglutide 5mg/mL injection, 0.5mL vi… 2023-04-26 Tried and True Granola Co. Naturally Swee… 2023-04-26

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Diamond Visions Recalls Plush Monkey Toys… 2023-04-27 Lucky Global Recalls Lelinta Multi-Purpos… 2023-04-20 MEKTOVI (binimetinib) tablets, 15 mg, 180… 2023-04-19 Simvastatin USP, 10 mg, Rx only, Intas Ph… 2023-05-10

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported April 26, 2023. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026